Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002648 | 0.84 | S1PR1 (0.33) | S1PR1 | |
| SCHEMBL18997669 | 0.77 | S1PR1 (0.32) | S1PR1 | |
| SCHEMBL21536857 | 0.71 | PGR (0.32) | S1PR1 | |
| SCHEMBL18498842 | 0.71 | — | — | |
| SCHEMBL9689168 | 0.65 | ALDH1A1 (0.37) | S1PR1 | |
| SCHEMBL15359895 | 0.61 | — | — | |
| SCHEMBL22827234 | 0.61 | GAA (0.37) | — | |
| SCHEMBL26581819 | 0.58 | ADRA2C (0.34) | — | |
| SCHEMBL27263675 | 0.57 | ALDH1A1 (0.31) | — | |
| SCHEMBL27263690 | 0.57 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | S1PR1 1204/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | S1PR1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.